CervoMed and EIP Pharma Enter into A Merger Agreement

An oral stress enzyme blocker is being researched for the therapy of dementia and numerous other progressive brain illnesses.

It is a chemical that breaks through the blood brain barrier, which effectively inhibits the activity of p38MAP kinase alpha. P38MAP is also a major contributor neural & synaptic damage which is brought on by inflammation.

CEO at CervoMed, John Alam stated “We are excited about the potential for neflamapimod to be the first-to-market disease-modifying drug therapy for DLB, with the potential to reverse and slow the progression of synaptic dysfunction”

COO at CervoMed, Robert Cobuzzi added “I look forward to working with CervoMed in my new role as COO, contributing to the company’s efforts in our mission of bringing new medicines to patients living with degenerative diseases of the brain.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved